Delving into the Latest Updates on Tianjin Gudui Biomedical Technology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Immune System Diseases

Hemic and Lymphatic Diseases

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	6
Immune System Diseases	3
Hemic and Lymphatic Diseases	3
Endocrinology and Metabolic Disease	2
Infectious Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	7
Chemical drugs	1

Top 5 Target	Count

HDACs(Histone deacetylase)	1

主要目的：评价健康研究参与者单次和多次口服GD-20片的安全性和耐受性；次要目的：评价健康研究参与者单次和多次口服GD-20片的药代动力学特征。探索性目的：探索健康研究参与者单次口服GD-20片的人体排泄率数据和主要排泄途径。

[Translation]

Primary objective: To evaluate the safety and tolerability of single and multiple oral administration of GD-20 tablets in healthy research participants; Secondary objective: To evaluate the pharmacokinetic characteristics of single and multiple oral administration of GD-20 tablets in healthy research participants. Exploratory objective: To explore the human excretion rate data and main excretion pathways of single oral administration of GD-20 tablets in healthy research participants.

Start Date-

Sponsor / Collaborator

Tianjin Gudui Biomedical Technology Co., Ltd.

100 Clinical Results associated with Tianjin Gudui Biomedical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Tianjin Gudui Biomedical Technology Co., Ltd.

Login to view more data

100 Deals associated with Tianjin Gudui Biomedical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Tianjin Gudui Biomedical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

5

Preclinical

IND Application

1

Phase 1 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

GD-20	Multiple Sclerosis More	Phase 1
GD-19(Tianjin Gudui )	-	IND Application
GD-12	Multiple Myeloma More	Preclinical
GD-07	Lung Cancer More	Preclinical
GD-17	Gastrointestinal Neoplasms More	Preclinical